NP Screen™ is a privately owned company. The company has an experienced management team and there is significant market potential for the company’s molecular genetic test for nasopharyngeal cancer, known as NP Screen™.
“From Hong Kong to Singapore, and California to Nigeria, customer feedback on our NP Screen™ product has been extremely positive,” says John Wilms, Director of Business Development for NP Screen™. “In our current financial environment, raising capital from investors demonstrates the strength of our company’s business model and team, and our prospects for sustainable, rapid growth.”
NP Screen™ represents an excellent investment opportunity, especially in biotechnology/medical device industry. The company already sells a product that meets a clear market need for an early stage screening test for a very challenging cancer, and is established in a number of countries around the world.
Please contact us at email@example.com for further information.